This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like ...

While Novo Nordisk and Lilly are the undisputed leaders in weight management right now, a number of pharmaceutical companies ...

With new weight-loss drugs hailed as ‘miracle’ medicines, Harriet Symonds explores whether their increasing popularity should ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

The sizeable new round follows the announcement of phase 1 data for its lead asset MET-097i in September, and according to ...

A manufacturer-funded study found a significant decrease in annual total medical costs in patients with overweight/obesity ...

The decision by Novo Nordisk to discontinue the insulin pens will force patients to revert to syringes, complicating diabetes care for millions of people.

Novo Nordisk, which manufactures weight-loss drug Wegovy and diabetes medication Ozempic, has asked the US authorities to ...

As the controlling shareholder of Novo Nordisk, a leading Danish pharmaceutical company, the takeover emerges amidst rising ...

Studies also show that incretin-based therapies like Wegovy and Mounjaro are much less effective ... In 2023, Embark Biotech was acquired by Novo Nordisk to develop next generation therapeutics for ...

US Food and Drug Administration (FDA) regulations allow human drug compounding — in which licensed pharmacists or physicians ...